Q1 2026 EPS Estimates for Glaukos Co. Raised by Zacks Research (NYSE:GKOS)

Glaukos Co. (NYSE:GKOS) – Equities researchers at Zacks Research raised their Q1 2026 EPS estimates for Glaukos in a research note issued to investors on Monday, June 24th. Zacks Research analyst I. Bandyopadhyay now expects that the medical instruments supplier will earn ($0.24) per share for the quarter, up from their previous estimate of ($0.33). The consensus estimate for Glaukos’ current full-year earnings is ($2.24) per share. Zacks Research also issued estimates for Glaukos’ FY2026 earnings at ($0.54) EPS.

Several other research firms have also issued reports on GKOS. Jefferies Financial Group raised shares of Glaukos from a “hold” rating to a “buy” rating and increased their target price for the stock from $84.00 to $125.00 in a research note on Monday, May 6th. Needham & Company LLC increased their target price on shares of Glaukos from $108.00 to $113.00 and gave the stock a “buy” rating in a research note on Thursday, May 2nd. Stifel Nicolaus increased their target price on shares of Glaukos from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, June 5th. Truist Financial reissued a “buy” rating and set a $125.00 target price (up from $120.00) on shares of Glaukos in a research note on Thursday, May 2nd. Finally, Mizuho lifted their price objective on Glaukos from $85.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $112.27.

Glaukos Price Performance

NYSE:GKOS opened at $116.66 on Wednesday. The firm’s fifty day moving average is $108.34 and its two-hundred day moving average is $95.33. The company has a debt-to-equity ratio of 0.78, a quick ratio of 4.68 and a current ratio of 5.38. Glaukos has a one year low of $59.22 and a one year high of $116.91. The firm has a market cap of $5.88 billion, a price-to-earnings ratio of -40.51 and a beta of 1.09.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.12). Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The business had revenue of $85.60 million during the quarter, compared to analysts’ expectations of $79.60 million. During the same period in the previous year, the company posted ($0.59) earnings per share. Glaukos’s revenue for the quarter was up 15.8% compared to the same quarter last year.

Institutional Trading of Glaukos

Several institutional investors have recently made changes to their positions in GKOS. Opaleye Management Inc. purchased a new stake in Glaukos in the first quarter valued at approximately $809,000. Cetera Advisors LLC purchased a new stake in Glaukos in the first quarter valued at approximately $213,000. Iron Triangle Partners LP raised its position in Glaukos by 75.6% in the first quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock valued at $40,500,000 after purchasing an additional 184,919 shares during the period. Bellevue Group AG purchased a new stake in Glaukos in the first quarter valued at approximately $5,273,000. Finally, Magnetar Financial LLC purchased a new stake in Glaukos in the first quarter valued at approximately $2,338,000. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Insiders Place Their Bets

In other Glaukos news, COO Joseph E. Gilliam sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $113.50, for a total value of $283,750.00. Following the transaction, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at approximately $11,559,407.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Marc Stapley sold 6,250 shares of Glaukos stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $112.80, for a total transaction of $705,000.00. Following the sale, the director now owns 32,360 shares of the company’s stock, valued at approximately $3,650,208. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Joseph E. Gilliam sold 2,500 shares of Glaukos stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $113.50, for a total transaction of $283,750.00. Following the sale, the chief operating officer now directly owns 101,845 shares in the company, valued at approximately $11,559,407.50. The disclosure for this sale can be found here. Insiders have sold 81,475 shares of company stock valued at $8,387,713 in the last ninety days. 6.40% of the stock is currently owned by corporate insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.